<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Metabolic factors such as glycemic control, <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo>, and <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo> are important considerations in the treatment of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In the RENAAL (Reduction of End Points in Type 2 <z:mp ids='MP_0002055'>Diabetes</z:mp> With the <z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> <z:chebi fb="68" ids="48706">Antagonist</z:chebi> <z:chebi fb="0" ids="6541">Losartan</z:chebi>) study, <z:chebi fb="0" ids="6541">losartan</z:chebi> reduced renal outcomes in the patient population </plain></SENT>
<SENT sid="2" pm="."><plain>This post hoc analysis of the RENAAL study reports the effects of <z:chebi fb="0" ids="6541">losartan</z:chebi> on selected metabolic parameters and assesses the relationship between baseline values of metabolic parameters and the primary composite end point or <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: Glycemic control (HbA(1c)) and serum <z:chebi fb="23" ids="18059">lipid</z:chebi>, <z:chebi fb="3" ids="27226">uric acid</z:chebi>, and <z:chebi fb="120" ids="26216">potassium</z:chebi> levels were compared between the <z:chebi fb="0" ids="6541">losartan</z:chebi> and placebo groups over time, and baseline levels were correlated with the risk of reaching the primary composite end point (doubling of serum <z:chebi fb="0" ids="16737">creatinine</z:chebi>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>, or <z:hpo ids='HP_0011420'>death</z:hpo>) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> alone </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="0" ids="6541">Losartan</z:chebi> did not adversely affect glycemic control or serum <z:chebi fb="23" ids="18059">lipid</z:chebi> levels </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="6541">Losartan</z:chebi>-treated patients had lower total (227.4 vs. 195.4 mg/dl) and <z:chebi fb="15" ids="39026">LDL</z:chebi> (142.2 vs. 111.7 mg/dl) cholesterol </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="6541">Losartan</z:chebi> was associated with a mean increase of up to 0.3 mEq/l in serum <z:chebi fb="120" ids="26216">potassium</z:chebi> levels; however, the rate of <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo>-related discontinuation was similar between the placebo and <z:chebi fb="0" ids="6541">losartan</z:chebi> groups </plain></SENT>
<SENT sid="7" pm="."><plain>Univariate analysis revealed that baseline total and <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels were associated with increased risk of developing the primary composite end point </plain></SENT>
<SENT sid="8" pm="."><plain>Similarly, total and <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> were also associated with increased risk of developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Overall, <z:chebi fb="0" ids="6541">losartan</z:chebi> was well tolerated by patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> and was associated with a favorable effect on the metabolic profile of this population </plain></SENT>
</text></document>